ArticleToxicological sciences : an official journal of the Society of Toxicology2008
Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells.
Article in Toxicological sciences : an official journal of the Society of Toxicology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 124 citations in OpenAlex.
- Trial
- Estrogen receptor 1 activation suppresses microglia-derived Tnf-α signaling as a photoreceptor self-protection mechanism.Journal of neuroinflammation · 2025Article
- Estrogen receptor β inhibits breast cancer migration and promotes its apoptosis through NF-κB/IL-8 signaling.Translational cancer research · 2025Article
- Antiproliferative Role of Natural and Semi-Synthetic Tocopherols on Colorectal Cancer Cells Overexpressing the Estrogen Receptor β.International journal of molecular sciences · 2025Article
- Efficient Consecutive Synthesis of Fluorinated Isoflavone Analogs, X-Ray Structures, Hirshfeld Analysis, and Anticancer Activity Assessment.Molecules (Basel, Switzerland) · 2025Article
- Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity.Current trends in immunology · 2025Article
- Article
- Estrogen Receptor Signaling in Breast Cancer.Cancers · 2023Review
- Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.Cancers · 2023Review
- Article
- Protein-Targeted Degradation Agents Based on Natural Products.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.Breast cancer research and treatment · 2022Article
- An approach to uncover the relationship between 17b-estradiol and ESR1/ESR2 ratio in the regulation of canine corpus luteum.Frontiers in veterinary science · 2022Article
- HPTE-Induced Embryonic Thymocyte Death and Alteration of Differentiation Is Not Rescued by ERα or GPER Inhibition but Is Exacerbated by Concurrent TCR Signaling.International journal of molecular sciences · 2021Article
- The Potential Effects of Phytoestrogens: The Role in Neuroprotection.Molecules (Basel, Switzerland) · 2021Review
- Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health.Nutrients · 2020Review
- Estrogen receptor alpha (ERα)-mediated coregulator binding and gene expression discriminates the toxic ERα agonist diethylstilbestrol (DES) from the endogenous ERα agonist 17β-estradiol (E2).Cell biology and toxicology · 2020Article
- Inter-Individual Variation in Response to Estrogen in Human Breast Explants.Journal of mammary gland biology and neoplasia · 2020Article
- Hypoxia differentially regulates estrogen receptor alpha in 2D and 3D culture formats.Archives of biochemistry and biophysics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer cells show overexpression of estrogen receptor (ER) alpha relative to ERbeta compared to normal breast tissues. This observation has lead to the hypothesis that ERbeta may modulate the proliferative effect of ERalpha. This study investigated how variable cellular expression ratios of the ERalpha and ERbeta modulate the effects on cell proliferation induced by ERalpha or ERbeta agonists, respectively. Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator. The effects of these selective estrogen receptor modulators (SERMs) and of the model compound E2 on the proliferation of T47D human breast cancer cells with tetracycline-dependent expression of ERbeta (T47D-ERbeta) were characterized. E2-induced cell proliferation of cells in which ERbeta expression was inhibited was similar to that of the T47D wild-type cells, whereas this E2-induced cell proliferation was no longer observed when ERbeta expression in the T47D-ERbeta cells was increased. In the T47D-ERbeta cell line, DPN also appeared to be able to suppress cell proliferation when levels of ERbeta expression were high. In the T47D-ERbeta cell line, PPT was unable to suppress cell proliferation at all ratios of ERalpha/ERbeta expression, reflecting its ability to activate only ERalpha and not ERbeta. It is concluded that effects of estrogen-like compounds on cell proliferation are dependent on the actual ERalpha/ERbeta expression levels in these cells or tissues and the potential of the estrogen agonists to activate ERalpha and/or ERbeta.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.